Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 5, 2013, Pages 568-574

  Tsimberidou, Apostolia M ^a   Wierda, William G ^a   Wen, Sijin ^a   Plunkett, William ^a   O'Brien, Susan ^a   Kipps, Thomas J ^b   Jones, Jeffrey A ^c   Badoux, Xavier ^a   Kantarjian, Hagop ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

OFAR; Refractory CLL; Richter syndrome; SCT; Therapy

Indexed keywords

CYTARABINE; FLUDARABINE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; AIRWAY OBSTRUCTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BLEEDING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; DEHYDRATION; DIARRHEA; DYSPNEA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFECTION; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTIPLE ORGAN FAILURE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RICHTER SYNDROME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING;

OFAR; REFRACTORY CLL; RICHTER SYNDROME; SCT; THERAPY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 84884154021     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.012     Document Type: Conference Paper

References (26)

1. M.N. Richter Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia Am J Pathol 4 1928 285 292
2. A.M. Tsimberidou, and M.J. Keating Richter syndrome: biology, incidence, and therapeutic strategies Cancer 103 2005 216 228
3. A.M. Tsimberidou, and S. O'Brien Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation J Clin Oncol 24 2006 2343 2351
4. W.S. Velasquez, F. Cabanillas, and P. Salvador Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) Blood 71 1988 117 122
5. O.W. Press, R. Livingston, and J. Mortimer Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation J Clin Oncol 9 1991 423 431
6. M. Martelli, M. Vignetti, and P.L. Zinzani High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study J Clin Oncol 14 1996 534 542
7. T. Philip, F. Chauvin, and J. Armitage Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation Blood 77 1991 1587 1592
8. W.S. Velasquez, P. McLaughlin, and S. Tucker ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study J Clin Oncol 12 1994 1169 1176
9. M.J. Watts, S.J. Ings, and D. Leverett ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients Br J Cancer 82 2000 278 282
10. M.A. Ozturk, I. Barista, and M.K. Altundag Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin Chemotherapy 48 2002 252 258
11. Y. Kidani, M. Noji, and T. Tashiro Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers Gann 71 1980 637 643
12. G. Mathe, Y. Kidani, and M. Segiguchi Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum Biomed Pharmacother 43 1989 237 250
13. P. Chollet, M.A. Bensmaine, and S. Brienza Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer Ann Oncol 7 1996 1065 1070
14. Y.F. Wang, J.E. Curtis, and J. Lipton Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo Leukemia 5 1991 522 527
15. L.Y. Yang, L. Li, and M.J. Keating Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair Mol Pharmacol 47 1995 1072 1079
16. L. Li, M.J. Keating, W. Plunkett, and L.Y. Yang Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance Mol Pharmacol 52 1997 798 806
17. L. Li, X. Liu, and A.B. Glassman Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro Cancer Res 57 1997 1487 1494
18. V. Gandhi, B. Nowak, and M.J. Keating Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy Blood 74 1989 2070 2075
19. A.M. Tsimberidou, W.G. Wierda, and W. Plunkett Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia J Clin Oncol 26 2008 196 203
20. M.A. Moufarij, D. Sampath, and M.J. Keating Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal Blood 108 2006 4187 4193
21. B.D. Cheson, S.J. Horning, and B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
22. B.D. Cheson, J.M. Bennett, and M. Grever National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 1996 4990 4997
23. A.M. Tsimberidou, H.M. Kantarjian, and J. Cortes Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia Cancer 97 2003 1711 1720
24. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242
25. X.C. Badoux, M.J. Keating, and X. Wang Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia Blood 118 2011 2085 2093
26. X.C. Badoux, M.J. Keating, and X. Wang Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL Blood 117 2011 3016 3024